Literature DB >> 28081955

Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

David Roife1, Ya'an Kang2, Li Wang3, Bingliang Fang3, Stephen G Swisher3, Jeffrey E Gershenwald2, Shanna Pretzsch4, Colin P Dinney4, Matthew H G Katz2, Jason B Fleming5.   

Abstract

BACKGROUND: Patient-derived xenografts have recently become a powerful tool for cancer research and may be used to guide personalized therapy. Thus far, patient-derived xenografts have been grown from tumor tissue obtained after operative resection; however, many cancer patients never undergo operative intervention for a variety of reasons. We hypothesized that xenograft tumors could be grown from smaller volumes of patient tissue, such as those obtained during diagnostic biopsies.
METHODS: Surgical specimens were obtained after resection of primary or metastatic lesions of the following cancers: pancreatic carcinoma, non-small cell lung cancer, bladder (urothelial) carcinoma, and melanoma. At least 10 cases of each cancer were included in this study. To mimic clinical biopsies, small fragments of the surgical specimens were biopsied with a 22-gauge needle, and the needle contents were injected subcutaneously in immunocompromised mice. The tumor fragment from which the biopsy was taken was also implanted subcutaneously in the contralateral side of the same mouse as a control.
RESULTS: Success rates of the traditional method of xenograft implantation ranged from 27.3%-70%. Success rates of the fine needle aspirate technique ranged from 0%-36.4%. An attempt to engraft a percutaneous core needle liver biopsy of a metastatic pancreatic adenocarcinoma also was successful.
CONCLUSION: We have found that it is possible to engraft fine needle aspirates and core biopsies of solid tumors in order to generate patient-derived xenografts. This may open up xenografting to a wider cancer patient population than previously possible.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28081955      PMCID: PMC5404969          DOI: 10.1016/j.surg.2016.11.020

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  28 in total

1.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

2.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations.

Authors:  L Gorunova; M Höglund; A Andrén-Sandberg; S Dawiskiba; Y Jin; F Mitelman; B Johansson
Journal:  Genes Chromosomes Cancer       Date:  1998-10       Impact factor: 5.006

4.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

5.  Allelotype of pancreatic adenocarcinoma using xenograft enrichment.

Authors:  S A Hahn; A B Seymour; A T Hoque; M Schutte; L T da Costa; M S Redston; C Caldas; C L Weinstein; A Fischer; C J Yeo
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Rapid detection and profiling of cancer cells in fine-needle aspirates.

Authors:  Hakho Lee; Tae-Jong Yoon; Jose-Luiz Figueiredo; Filip K Swirski; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

Review 7.  Patient-derived xenograft models: an emerging platform for translational cancer research.

Authors:  Manuel Hidalgo; Frederic Amant; Andrew V Biankin; Eva Budinská; Annette T Byrne; Carlos Caldas; Robert B Clarke; Steven de Jong; Jos Jonkers; Gunhild Mari Mælandsmo; Sergio Roman-Roman; Joan Seoane; Livio Trusolino; Alberto Villanueva
Journal:  Cancer Discov       Date:  2014-07-15       Impact factor: 39.397

8.  ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Authors:  Michael P Kim; Jason B Fleming; Huamin Wang; James L Abbruzzese; Woonyoung Choi; Scott Kopetz; David J McConkey; Douglas B Evans; Gary E Gallick
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

10.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.

Authors:  Jennifer L Dembinski; Stefan Krauss
Journal:  Clin Exp Metastasis       Date:  2009-05-07       Impact factor: 5.150

View more
  7 in total

1.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

2.  Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens.

Authors:  Matthew C Hernandez; John R Bergquist; Jennifer L Leiting; Tommy Ivanics; Lin Yang; Rory L Smoot; David M Nagorney; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2019-02-12       Impact factor: 3.452

Review 3.  [Advances in Patient Derived Tumor Xenograft (PDTX) Model from Lung Cancer].

Authors:  Baodong Qin; Xiaodong Jiao; Lingyan Yuan; Ke Liu; Yuansheng Zang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-10-20

4.  A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine.

Authors:  Anne T Collins; Shona H Lang
Journal:  PeerJ       Date:  2018-11-21       Impact factor: 2.984

5.  Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples.

Authors:  Sun Il Choi; A-Ra Jeon; Min Kyeong Kim; Yu-Sun Lee; Ji Eun Im; Jung-Wook Koh; Sung-Sik Han; Sun-Young Kong; Kyong-Ah Yoon; Young-Hwan Koh; Ju Hee Lee; Woo Jin Lee; Sang-Jae Park; En Kyung Hong; Sang Myung Woo; Yun-Hee Kim
Journal:  Front Oncol       Date:  2019-09-13       Impact factor: 6.244

6.  An improved method to build lung cancer PDX models by surgical resection samples and its association with B7-H3 expression.

Authors:  Yuxuan Wang; Biao Zhang; Haitao Huang; Tingjing Wang
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

7.  Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies.

Authors:  Daniel Strüder; Theresa Momper; Nina Irmscher; Mareike Krause; Jan Liese; Sebastian Schraven; Annette Zimpfer; Sarah Zonnur; Ann-Sophie Burmeister; Björn Schneider; Bernhard Frerich; Robert Mlynski; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  J Exp Clin Cancer Res       Date:  2021-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.